Horizon Strengthens Board with Appointment of Dr. Ian Gilham
News Aug 02, 2013
Horizon Discovery (Horizon) has announced the appointment of Dr. Ian Gilham as a non-executive director.
Ian is currently non-executive chairman of Multiplicom NV, focused on the development and commercialization of DNA sequencing products; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products.
He is also Director of Stowheath Ltd., which offers advisory services to private equity companies and corporate finance organizations investing in clinical diagnostics and medical device companies.
Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.
Commenting on the announcement, Dr. Darrin M Disley, CEO of Horizon said: “I would like to welcome Ian to Horizon’s board of directors. His commercial and investor relations experience will be highly valuable to the company as we continue to develop as a world-leading translational genomics organization.”
Dr. Gilham noted: “Horizon is one of the UK’s most promising life science companies. I’m delighted to join the board at this stage of the organization’s development.”
Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE
Researchers have discovered a navigational gene in glass catfish called the electromagnetic-perceptive gene, or EPG, that responds to certain magnetic waves. These findings have the potential to revolutionize treatments for humans and help those who suffer from tremors related to Parkinson’s and seizures associated with epilepsy.